Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $0.0.

  • Xeris Biopharma Holdings' EPS (Basic) rose 10344.97% to $0.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.1, marking a year-over-year increase of 7727.27%. This contributed to the annual value of -$0.37 for FY2024, which is 1697.52% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' EPS (Basic) stood at $0.0, which was up 10344.97% from -$0.01 recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' EPS (Basic) registered a high of $0.0 during Q3 2025, and its lowest value of -$0.44 during Q4 2021.
  • Over the past 5 years, Xeris Biopharma Holdings' median EPS (Basic) value was -$0.12 (recorded in 2023), while the average stood at -$0.16.
  • Per our database at Business Quant, Xeris Biopharma Holdings' EPS (Basic) tumbled by 2222.22% in 2024 and then surged by 10344.97% in 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' EPS (Basic) (Quarter) stood at -$0.44 in 2021, then soared by 77.27% to -$0.1 in 2022, then grew by 10.0% to -$0.09 in 2023, then skyrocketed by 61.29% to -$0.03 in 2024, then skyrocketed by 110.89% to $0.0 in 2025.
  • Its EPS (Basic) stands at $0.0 for Q3 2025, versus -$0.01 for Q2 2025 and -$0.06 for Q1 2025.